| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/27/2002 | WO2002030393A3 Polymeric delivery formulations of leuprolide with improved efficacy |
| 06/27/2002 | WO2002030390A3 Method for producing powdery formulations |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002015881A3 Use of a porous carrier |
| 06/27/2002 | WO2002009704A3 Pharmaceutical composition for transdermal delivery of befloxatone |
| 06/27/2002 | WO2002005844A3 Protein complex serving as a vehicle for orally administerable medicaments |
| 06/27/2002 | WO2002002597A3 Peptide extended glycosylated polypeptides |
| 06/27/2002 | WO2002002182A3 Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system |
| 06/27/2002 | WO2002000196A3 Wet milling process |
| 06/27/2002 | WO2001093853A8 Management of snoring by oral administration of dimethyl sulfone |
| 06/27/2002 | WO2001092288A3 Cobalamin compounds useful as antibiotic agents and as imaging agents |
| 06/27/2002 | WO2001081426A3 Rgd (arg-gly-asp) coupled to (neuro)peptides |
| 06/27/2002 | WO2001081182A3 Improved method and apparatus for generating an aerosol |
| 06/27/2002 | WO2001076640A3 Chemically modified novel erythropoietin stimulating protein compositions and methods |
| 06/27/2002 | WO2001074849A3 Binding peptides for carcinoembryonic antigen (cea) |
| 06/27/2002 | WO2001074330A3 Method for treating dry eye |
| 06/27/2002 | WO2001041823A8 Radioactive compositions and methods of use thereof |
| 06/27/2002 | WO2001030393A8 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 06/27/2002 | WO2001014536A3 Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence |
| 06/27/2002 | WO2001012217A9 Therapeutic antibody against muc-1 antigen and methods for their use |
| 06/27/2002 | WO2000050008A9 Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| 06/27/2002 | US20020082745 Method and system for producing customized cosmetic and pharmaceutical formulations on demand |
| 06/27/2002 | US20020082620 Bioactive materials for aneurysm repair |
| 06/27/2002 | US20020082400 Immunoconjugate for use in human therapeutics and diagnostics |
| 06/27/2002 | US20020082373 Fluid thickeners comprising neutralized crosslinked polymers of acrylamidoalkylsulonic acids and N-vinylamides |
| 06/27/2002 | US20020082362 For use in pharmaceutical and biomedical applications, stability; conjugates of polymers with drugs anticancer drugs used in cancer therapy |
| 06/27/2002 | US20020082345 Synthesis of high molecular weight non-peptidic polymer derivatives |
| 06/27/2002 | US20020082307 Useful for therapy of symptoms associated with respiratory illnesses |
| 06/27/2002 | US20020082306 Heating aqueous solution of polyoxyethylene-660-hydroxystearate, adding beta-carotene with stirring; adding ascorbyl palmitate and alpha-tocopoherol as antioxidant to solution; diluting with water |
| 06/27/2002 | US20020082304 Containing combination inhibitor, combination inhibitor which acts both to interfere with the isolation of sympathomimetic amine from the composition and to interfere with conversion of sympathomimetic amine to another drug |
| 06/27/2002 | US20020082301 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 06/27/2002 | US20020082237 Complexing a cationic polymer and/or cationic lipid with a polynucleotide in the presence of detergent, removing the detergent whereby a stable polynucleotide dellivery vehicle is produced |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082201 And pharmaceutically acceptable surfactant including sodium lauryl sulfate, buffering agent to provide pH of 3.0-7.0, 0.5-10.0 weight percent colloidal silicon dioxide |
| 06/27/2002 | US20020082199 Insoluble insulin compositions |
| 06/27/2002 | US20020082198 Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon |
| 06/27/2002 | US20020081739 Genetically engineering cells; obtain cell, obtain nucleotide sequences, adhere sequences to sheets, propel sheet into cells, recover transformed cells |
| 06/27/2002 | US20020081662 Radioiodinated sulfonated phenols and process therefore |
| 06/27/2002 | US20020081578 Nucleotide sequences coding preferential polypeptide for as anticarcinogenic agents |
| 06/27/2002 | US20020081334 Preparation of drug particles using evaporation precipitation into aqueous solutions |
| 06/27/2002 | US20020081331 Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| 06/27/2002 | US20020081315 Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 06/27/2002 | US20020081310 Apoptosis-related compounds and their use |
| 06/27/2002 | US20020081309 Conjugating a protein with polyethylene glycol (PEG), by deleting amino residue(s); for example, replacing protein arginine residues with lysine residues that provide a PEG attachment site; bioactivity |
| 06/27/2002 | US20020081303 Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders |
| 06/27/2002 | US20020081295 Virus-like particles for the induction of autoantibodies |
| 06/27/2002 | US20020081292 Anthelmintic composition |
| 06/27/2002 | US20020081267 Toothpaste, gel, or mouthwash comprising emulsifier, triclosan, and surfactant (cetylpyridinium chloride); anticaries agents |
| 06/27/2002 | US20020078948 Method for generating an aerosol |
| 06/27/2002 | CA2756207A1 Compositions of estrogen-cyclodextrin complexes |
| 06/27/2002 | CA2442181A1 Method for purification of lactose |
| 06/27/2002 | CA2436149A1 Novel in-situ forming controlled release microcarrier delivery system |
| 06/27/2002 | CA2432879A1 Anti-allergic complex molecules |
| 06/27/2002 | CA2432797A1 Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 06/27/2002 | CA2432638A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | CA2432310A1 Electrically responsive promoter system |
| 06/27/2002 | CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | CA2431964A1 Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| 06/27/2002 | CA2423331A1 Shark meat extract |
| 06/27/2002 | CA2397990A1 Propofol formulation with enhanced microbial inhibition |
| 06/26/2002 | EP1216714A1 Cellular and serum protein anchors and conjugates |
| 06/26/2002 | EP1216713A1 Compositions of estrogen-cyclodextrin complexes |
| 06/26/2002 | EP1216712A1 Cyclodextrin-drospirenone inclusion complexes |
| 06/26/2002 | EP1216700A1 Transdermal systems comprising (R)-(-)-methylphenyloxazolidinone derivatives, inhibitors of type IV phosphodiesterase |
| 06/26/2002 | EP1216699A1 Transdermal system comprising a highly potent progestin |
| 06/26/2002 | EP1216695A2 O/W Emulsions comprising a copolymer of ammonium acryloyl dimethyl taurate and vinylpyrrolidone |
| 06/26/2002 | EP1216686A2 Gel-creams of the o/w emulsion type containing one or more ammonium acryloyl dimethyltaurate/vinyl pyrrolidone copolymers |
| 06/26/2002 | EP1216066A1 Compositions for the treatment of wound contracture |
| 06/26/2002 | EP1216065A1 Silver-containing compositions, devices and methods for making |
| 06/26/2002 | EP1216060A2 Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| 06/26/2002 | EP1216059A2 Composition for ivf |
| 06/26/2002 | EP1216058A2 Process for lessening polymorphic conversion of a drug |
| 06/26/2002 | EP1216057A1 Stable calcitriol solution for packaging in vials |
| 06/26/2002 | EP1216053A2 Influenza vaccine |
| 06/26/2002 | EP1216051A1 Anti cancer agent and method of treatment of cancer |
| 06/26/2002 | EP1216048A2 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 06/26/2002 | EP1216045A2 Vasopressin agonist formulation and process |
| 06/26/2002 | EP1216044A1 Compositions having improved stability |
| 06/26/2002 | EP1216043A1 Retard form containing alpha-lipoic acid (derivatives) |
| 06/26/2002 | EP1216041A2 High lipid diet |
| 06/26/2002 | EP1216037A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 06/26/2002 | EP1216035A2 Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
| 06/26/2002 | EP1216033A1 Vasopressin antagonist formulation and process |
| 06/26/2002 | EP1216031A2 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 06/26/2002 | EP1216030A1 Anti-inflammatory pharmaceutical formulations |
| 06/26/2002 | EP1216029A1 Pharmaceutical carrier formulation |
| 06/26/2002 | EP1216028A1 Biodegradable excipient systems for therapeutically active substances and method for producing the same |
| 06/26/2002 | EP1216026A1 Compositions of tocol-soluble therapeutics |
| 06/26/2002 | EP1216025A1 Dispersion formulations containing lipase inhibitors |
| 06/26/2002 | EP1073414B1 Use of pharmaceutical compositions capable of being gelled in periodontology |
| 06/26/2002 | EP1058538B1 Fast disintegrating tablets |
| 06/26/2002 | EP1051155B1 Nasal solutions |
| 06/26/2002 | EP1037609A4 Aqueous insecticidal pour-on formulation |
| 06/26/2002 | EP1007011A4 Lock and key micelles |
| 06/26/2002 | EP1003510A4 Method for treating headache pain with topical local anesthetic compositions |
| 06/26/2002 | EP0973506B1 Process for preparing solid pharmaceutical dosage forms |
| 06/26/2002 | EP0850049B1 Composition for ph-dependent controlled release of active ingredients and methods for producing it |
| 06/26/2002 | EP0830137A4 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 06/26/2002 | EP0783296B1 Novel compositions for the introduction of polyanionic materials into cells |
| 06/26/2002 | CN1355842A Methods for making proteins containing free cysteine residues |